References
- Miura JT, Johnston FM, Gamblin TC, et al. (2014). Current trends in the management of malignant peritoneal mesothelioma. Ann Surg Oncol 21:3947–53.
- Lin RT, Takahashi K, Karjalainen A, et al. (2007). Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. Lancet 369:844–9.
- Leblay N, Lepretre F, Le Stang N, et al. (2017). BAP1 is altered by copy number loss, mutation, and/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas. J Thorac Oncol 12:724--33.
- Kusamura S, Torres Mesa PA, Cabras A, et al. (2016). The role of Ki-67 and pre-cytoreduction parameters in selecting diffuse malignant peritoneal mesothelioma (DMPM) patients for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 23:1468–73.
- Lee M, Alexander HR, Burke A. (2013). Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy. Pathology 45:464–73.
- Pass HI, Levin SM, Harbut MR, et al. (2012). Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 367:1417–27.
- Arnold DT, De Fonseka D, Hamilton FW, et al. (2017). Prognostication and monitoring of mesothelioma using biomarkers: a systematic review. Br J Cancer 116:731--41.
- Cao Q, Lu M, Heath J, et al. (2012). 18F-FDG PET/CT in a recurrent diffuse malignant peritoneal mesothelioma. Clin Nucl Med 37:492–4.
- Rajeev R, Klooster B, Turaga KK. (2016). Impact of surgical volume of centers on post-operative outcomes from cytoreductive surgery and hyperthermic intra-peritoneal chemoperfusion. J Gastrointest Oncol 7:122–8.
- Alexander HR Jr. (2010). Surgical treatment of malignant peritoneal mesothelioma: past, present, and future. Ann Surg Oncol 17:21–2.
- Alexander HR Jr, Bartlett DL, Pingpank JF, et al. (2013). Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery 153:779–86.
- Sugarbaker PH, Turaga KK, Alexander HR Jr, et al. (2016). Management of malignant peritoneal mesothelioma using cytoreductive surgery and perioperative chemotherapy. J Oncol Pract 12:928–35.
- Helm JH, Miura JT, Glenn JA, et al. (2015). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol 22:1686–93.
- Sugarbaker PH, Chang D. (2017). Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol pii: S0748--7983(17):30059--8.
- Yan TD, Deraco M, Baratti D, et al. (2009). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27:6237–42.
- Kindler HL. (2013). Peritoneal mesothelioma: the site of origin matters. Am Soc Clin Oncol Educ Book 182–8. doi:10.1200/EdBook_AM.2013.33.182
- Kepenekian V, Elias D, Passot G, et al. (2016). Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study. Eur J Cancer 65:69–79.
- Stahel RA, Riesterer O, Xyrafas A, et al. (2015). Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol 16:1651–8.